Selected topics from the 9th Conference on Retroviruses and Opportunistic Infections.
Chaisson
Richard E
RE
Gebo
Kelly
K
Flexner
Charles
C
Gallant
Joel E
JE
Lucas
Gregory M
GM
Bartlett
John G
JG
D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D017088:AIDS-Related Opportunistic Infections / Q000150:complications* / Q000188:drug therapy; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D015224:Dideoxynucleosides / Q000009:adverse effects; D004342:Drug Hypersensitivity; D023581:HIV Fusion Inhibitors / Q000494:pharmacology; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D019428:HIV Integrase Inhibitors / Q000494:pharmacology; D015235:HLA-B Antigens / Q000235:genetics / Q000276:immunology; D006526:Hepatitis C / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D006801:Humans; D007167:Immunotherapy; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors / Q000378:metabolism; D014376:Tuberculosis / Q000150:complications / Q000188:drug therapy; D000099227:Abacavir
D016915:AIDS Vaccines; D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D023581:HIV Fusion Inhibitors; D019428:HIV Integrase Inhibitors; D015235:HLA-B Antigens; D019707:Receptors, Chemokine; D000099227:Abacavir; C103707:HLA-B57 antigen